UNSPSC 51172470: Homatropine/opium/pectin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.

UNSPSC 51172470 Homatropine/opium/pectin is a Commodity code covering pharmaceutical formulations and related testing services that state and local governments buy primarily for corrections and criminal justice applications, along with multi-source generic pharmaceutical supply agreements serving broader state and local health care needs. Recent solicitations show two distinct procurement streams: offender drug testing services (specimen collection, immunoassay screening, and confirmatory testing via LC/MS/MS or GC/MS) and generic pharmaceutical supply contracts serving multiple participating jurisdictions through cooperative purchasing vehicles. The issuing bodies range from county-level corrections and community supervision departments to state health agencies and multistate cooperative purchasing alliances. Collin County Community Supervision and Corrections Department (Texas) is a repeat buyer of specimen collection and drug testing services, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) operates a statewide and multi-state pharmaceutical supply contract spanning state and local government facilities.

Recent activity concentrates in Texas and the Upper Midwest. Collin County issued RFP 2026-327 for Offender Specimen Collection and Drug Testing Services with a response deadline of July 23, 2026, seeking staffing of two collection sites in Plano and McKinney, operation of an Interactive Voice Response system for randomized testing notifications, and immunoassay screening with confirmatory testing, with an estimated contract value of $600,000 over two years and three optional one-year renewals. MMCAP issued a Request for Proposal (RFP) on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions, with awarded vendors effective July 1, 2026. The Texas Health and Human Services Commission also issued Request for Information RFI No. HHS0017013 in March 2026 to gather vendor capabilities for a potential Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, though this RFI does not yet represent a formal procurement commitment.